Location of Centers Participating in the CIBMTR 2013 Transplant Activity in the US Allogeneic Stem Cell Sources by Recipient Age Autologous Stem Cell Sources by Recipient Age Trends in Transplants ID: 774807
Download Presentation The PPT/PDF document " Current Uses and Outcomes of Hematopoie..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013
Slide2Location of Centers Participatingin the CIBMTR 2013
Slide3Transplant Activity in the US
Slide4Allogeneic Stem Cell Sources by Recipient Age
Slide5Autologous Stem Cell Sources by Recipient Age
Slide6Trends in Transplantsby Type and Recipient Age*
Slide7Trends in Transplants by Transplant Type and Recipient Age*
Slide8Indications for Hematopoietic Stem Cell Transplants in the US, 2011
Slide9Indications for Hematopoietic Stem Cell Transplants for Age ≤ 20 years, in the US, 2011
Slide10Allogeneic Transplants for Age ≤ 20 years, Registered with the CIBMTR
Slide11Allogeneic Transplants for Age > 20 years, Registered with the CIBMTR
Slide12Unrelated Donor Stem Cell Sourcesby Recipient Age
Slide13Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR
Slide14One-year Survival by Year of Transplant, Donor and Age, Worldwide
Slide15100-day Mortality after Autologous Transplants, 2010-2011
Slide16100-day Mortality after HLA-identical Sibling Transplants, 2010-2011
Slide17100-day Mortality after Unrelated Donor Transplants, 2010-2011
Slide18Causes of Death after Autologous Transplants done in 2010-2011
Slide19Causes of Death after HLA-identical Sibling Transplants done in 2010-2011
Slide20Causes of Death after Unrelated Donor Transplants done in 2010-2011
Slide21Allogeneic Transplants Registered with the CIBMTR
Slide22Allogeneic Transplants after Reduced Intensity Conditioning, by Donor Type, Registered with CIBMTR
Slide23Proportion of Allogeneic Transplants with Reduced Intensity Conditioning for Different Indications
Slide24Survival after HLA-identical Sibling Donor Transplants for AML, 2001-2011
Slide25Survival after Unrelated Donor Transplants for AML, 2001-2011
Slide26Survival after HLA-identical Sibling Donor Transplants for AML, Age < 20 years, 2001-2011
Slide27Survival after Allogeneic Transplants for MDS, 2001-2011
Slide28Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 years, 2001-2011
Slide29Survival after Unrelated Donor Transplants for ALL, Age < 20 years, 2001-2011
Slide30Survival after HLA-identical Sibling Donor Transplants for ALL, Age ≥ 20 years, 2001-2011
Slide31Survival after Unrelated Donor Transplants for ALL, Age ≥ 20 Years, 2001-2011
Slide32Survival after HLA-identical Sibling Donor Transplants for CML, 2001-2011
Slide33Survival after HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2001-2011
Slide34Survival after Allogeneic Transplants for SAA, 2001-2011
Slide35Survival after Autologous Transplants for Hodgkin Lymphoma, 2001-2011
Slide36Survival after Allogeneic Transplants for Hodgkin Lymphoma, 2001-2011
Slide37Survival after Autologous Transplants for Follicular Lymphoma, 2001-2011
Slide38Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2001-2011
Slide39Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2001-2010
Slide40Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2001-2011
Slide41Survival after Transplants for Mantle Cell Lymphoma, 2001-2011
Slide42Survival after Transplants for Multiple Myeloma, 2001-2011